ClinicalTrials.gg
Active, not recruitingNCT06724809ECU-NMO-304Updated Dec 19, 2025

Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

A Phase 3 interventional study of eculizumab in NMOSD and Neuromyelitis Optica Spectrum Disorders, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 7 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Neuromyelitis Optica by AstraZeneca — 3 open to participants now, 5 under way, 3 of them phase 3. Neuromyelitis Optica · AstraZeneca.

Started
2025
with 1 other
Phase 3
5 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Neuromyelitis Optica by AstraZeneca, this one is one of 2 that started in 2025, is one of 5 in phase 3, and was the 9th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

3 of the 11 studies in Neuromyelitis Optica by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Neuromyelitis Optica by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).

03

Conditions studied

  • NMOSD
  • Neuromyelitis Optica Spectrum Disorders

Browse trials for

Keywords

  • NMOSD
  • Neuromyelitis Optica Spectrum Disorders
  • eculizumab
  • anti-AQP4
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with diagnosis of NMOSD as defined by the 2015 international consensus diagnostic criteria
  • Anti-AQP4 antibody positive
  • At least 1 attack or relapse in the last 12 months prior to the Screening Period
  • EDSS score ≤ 7
  • If a participant enters the study receiving IST(s) for relapse prevention, the participant must be on a stable maintenance dose of IST(s) as follows, prior to screening and must remain on that dose for the duration of the study, unless the participant experiences a relapse
  • Female participants of must have a negative pregnancy test (serum HCG at screening
  • Male participants are eligible to participate if they agree to the following during the study intervention Treatment Period and for at least 5 months after the last dose of study intervention:

    • Refrain from donating fresh unwashed semen. PLUS, either,
    • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR
    • Must agree to use barrier as detailed below:

      • Agree to use a male condom when having sexual intercourse with a WOCBP who is not currently pregnant.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding, or intending to conceive during the course of the study
  • Prior history of N meningitidis infection or unresolved meningococcal disease
  • Any systemic bacterial or other infection which is in the opinion of the Investigator and has not been treated with appropriate antibiotics
  • Presence of fever ≥ 38 C within 7 days prior to study intervention administration on Day 1
  • to murine proteins or to one of the of study intervention
  • Use of rituximab, inebilizumab, or other B cell-depleting therapy within 6 months prior to Day 1 and during the study
  • Use of mitoxantrone or satralizumab within 3 months prior to screening and during the study
  • Use of IVIg within 3 weeks prior to screening
  • If a participant enters the study receiving oral (s) with or without other ISTs, the daily corticosteroid dose must be no more than prednisone 20 mg/day (or equivalent) prior to screening and the participant must remain on that dose for the duration of the study or until the participant experiences a relapse (specific medications listed in Section 6.9.1 may be allowed)
  • Has previously received treatment with C5 inhibitors
  • Participation in any other drug study or exposure to an investigational drug or device within 5 half-lives of treatment (if known) or 30 days, which is longer, before the first dose administration
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    eculizumab

    All participants will receive open-label eculizumab by intravenous infusion during the Treatment Period, starting on Day 1 for a total of up to 52 weeks.

    Drug: eculizumab

Interventions

  • Participants will receive eculizumab by intravenous (IV) infusion for 52 weeks.

06

What researchers measure

Primary outcomes

  1. The efficacy of eculizumab in anti-AQP4 antibody positive participants with NMOSD measured by Adjudicated On-trial annualized relapse rate (ARR).

    The mean (95% Confidence Interval) of patient-level Adjudicated On-trial annualized relapse rate (ARR)

    Time frame: Baseline through Week 52

  2. The efficacy of eculizumab in anti-AQP4 antibody positive participants with NMOSD measured by Adjudicated On-trial annualized relapse rate (ARR).

    Intercurrent Event (ICE): * ICE1: Premature discontinuation of study intervention * ICE2: Initiation of disallowed therapy or medicine

    Time frame: Baseline through Week 52

Secondary outcomes

  1. The efficacy of eculizumab by assessing change from baseline to end of study in Expanded Disability Status Scale (EDSS) Score

    Intercurrent Event (ICE): * ICE1: Premature discontinuation of study intervention * ICE2: Initiation of disallowed therapy or medicine * Summary measure: The mean (95% Confidence Interval) change from baseline to end of study in EDSS score

    Time frame: Baseline through Week 52

  2. The efficacy of eculizumab by assessing change from baseline to end of study in Ambulatory Function as Measured by Hauser Ambulation Index (HAI)

    Intercurrent Event (ICE): * ICE1: Premature discontinuation of study intervention * ICE2: Initiation of disallowed therapy or medicine * Summary measure: The mean (95% Confidence Interval) change from baseline to end of study in ambulatory function as measured by Hauser ambulation index (HAI)

    Time frame: Baseline through Week 52

  3. The efficacy of eculizumab by assessing change from baseline to end of study in European Quality of Life 5-Dimension Questionnaire (EQ-5D) Index Score

    Intercurrent Event (ICE): * ICE1: Premature discontinuation of study intervention * ICE2: Initiation of disallowed therapy or medicine * Summary measure: The mean (95% Confidence Interval) change from baseline to end of study in EQ-5D index score

    Time frame: Baseline through Week 52

  4. Change From Baseline to end of study in EQ-5D Visual Analogue Scale (VAS) Score

    Intercurrent Event (ICE): * ICE1: Premature discontinuation of study intervention * ICE2: Initiation of disallowed therapy or medicine * Summary measure: The mean (95% Confidence Interval) change from baseline to end of study in EQ-5D VAS

    Time frame: Baseline through Week 52

  5. Serum Eculizumab Concentrations Over Time

    Intercurrent Event (ICE): * ICE1: Premature discontinuation of study intervention * ICE2: Initiation of disallowed therapy or medicine * Summary measure: Mean serum eculizumab concentrations at all scheduled visits

    Time frame: Baseline through Week 52

  6. Serum Free Complement Component 5 (C5) Concentrations Over Time

    Intercurrent Event (ICE): * ICE1: Premature discontinuation of study intervention * ICE2: Initiation of disallowed therapy or medicine * Summary measure: Mean changes in serum free C5 concentrations at all scheduled visits

    Time frame: Baseline through Week 52

  7. Number of Treatment-emergent Antidrug Antibody (ADA) Positive Participants

    Intercurrent Event (ICE): * ICE1: Premature discontinuation of study intervention * ICE2: Initiation of disallowed therapy or medicine * Summary measure: Proportion of treatment-emergent ADA positive participants

    Time frame: Baseline through Week 52

  8. To characterize the overall safety of eculizumab in the treatment of NMOSD

    Number of participants with TEAEs, SAEs, and TEAEs leading to study intervention discontinuation, with abnormal vital signs, abnormal ECG readings, and abnormal laboratory tests results

    Time frame: Baseline through Week 52

07

Study locations

7 sites
  • Research Site
    Beijing, 100016, China
  • Research Site
    Dongguan, 523059, China
  • Research Site
    Jinan, 250012, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430030, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Dec 9, 2024
StartActual
Jan 16, 2025
Primary completionEst.
Dec 7, 2026
CompletionEst.
Dec 7, 2026
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06724809
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Jan 16, 2025
Primary completion
Dec 7, 2026 (estimated)
Completion
Dec 7, 2026 (estimated)
Last update
Dec 19, 2025

Study contacts

Xiangjun Chen, M.D
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion